A review of calcium supplements and cardiovascular disease risk

Robert P Heaney1, Stephen Kopecky, Kevin C Maki

  • 1Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE, USA.

Insights

Current evidence does not support a link between calcium supplements and cardiovascular events. Experts suggest current recommendations for bone health should remain unchanged.

Area of Science:

  • Nutrition Science
  • Cardiovascular Epidemiology
  • Bone Health Research

Background:

  • Concerns exist regarding potential cardiovascular risks associated with calcium supplement use.
  • Some studies suggest a possible association between calcium supplements and adverse cardiovascular events.
  • Existing research has limitations, including compliance issues and potential bias, questioning reported associations.

Purpose of the Study:

  • To critically evaluate the evidence linking calcium supplement intake to cardiovascular event risk.
  • To assess the strength, consistency, dose-response, and biological plausibility of the hypothesized relationship.
  • To determine if current evidence warrants a change in recommendations for calcium supplementation.

Main Methods:

  • Review of epidemiological studies and meta-analyses of randomized controlled trials.
  • Examination of subgroup analyses, including data from the Women's Health Initiative.
  • Application of Bradford Hill criteria for causal inference to assess the calcium-cardiovascular link.

Main Results:

  • Methodological limitations in studies reporting adverse cardiovascular events (e.g., bias, confounding) were identified.
  • Other cohort studies indicate no detrimental cardiovascular effects from dietary or supplemental calcium, with or without vitamin D.
  • Limited evidence supports plausible biological mechanisms connecting calcium supplements to adverse cardiovascular outcomes.

Conclusions:

  • The current evidence is insufficient to establish a causal relationship between calcium supplement use and increased cardiovascular disease risk.
  • Existing recommendations from the Institute of Medicine for calcium supplementation for bone health should be maintained.
  • Further research may be needed, but current data do not support altering supplementation guidelines based on cardiovascular concerns.

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...